Phase I trial of CF 102 in volunteers.
Phase of Trial: Phase I
Latest Information Update: 06 May 2008
At a glance
- Drugs Namodenoson (Primary)
- Indications Hepatitis B; Hepatitis C; Liver cancer; Liver disorders
- Focus Adverse reactions
- Sponsors Can-Fite BioPharma
- 06 May 2008 Status changed from recruiting to completed, as reported by Can-Fite.
- 19 Feb 2008 Can-Fite have reported that the first dose cohort has been completed.
- 19 Feb 2008 Status changed from initiated to recruiting as reported by Can-Fite Biopharma.